Ozempic-maker Novo Nordisk underwhelms investors with soft Wegovy pill sales
Novo Nordisk reported quarterly revenue of 3.2 billion Danish kroner (US$494 million), in line with analysts’ estimates, as Wegovy pill sales disappointed investors. CEO Mike Doustdar said demand was offset by lower prices and profitability should improve with higher doses. Novo’s CagriSema trial again underperformed Eli Lilly’s Zepbound, while Novo shares fell up to 7.1% in Copenhagen.
How this was made
The 30-second read
Why it matters
Novo’s Wegovy revenue matched estimates but disappointed versus launch expectations, while CagriSema again underperformed in a head-to-head comparison. Novo also raised its forecast for the worst sales/profit drop, and management cited lower prices offsetting demand. Lilly, by contrast, boosted its forecast and reported better-than-expected earnings, and the trial comparison favored Zepbound, driving relative strength.
Market read
This is a relative-competition update for the obesity trade, with concrete earnings and forecast details plus a pipeline efficacy read-through that can drive peer re-rating.
What to watch
The article notes weekly US prescriptions and oral market share capture, so the key debate may be pricing trajectory and dose ramp timing rather than demand destruction.
Background
The piece centers on Novo Nordisk’s Wegovy oral weight-loss pill sales and the competitive read-through from next-generation CagriSema versus Eli Lilly’s Zepbound.
Ticker impact
Novo Nordisk reported quarterly results with Wegovy pill revenue of 3.2 billion DKK, missing hype and raising 2027 competitiveness concerns.
Bearish bias for NVO until clearer evidence on demand, pricing, and CagriSema differentiation emerges.
The article ties the stock drop to specific Wegovy sales under-delivery, management commentary on lower prices, and another trial read-through where CagriSema lagged Zepbound.
Eli Lilly’s Zepbound outperformed in a CagriSema comparison, and Lilly shares surged after boosted forecast and better-than-expected earnings.
Bullish bias for LLY as investors re-rate obesity leadership and forecast confidence.
The text explicitly links CagriSema trial underperformance to Zepbound, and states Lilly boosted its forecast alongside better-than-expected earnings.
Market effects
Reinforces that obesity drug competition is shifting from launch hype to sustained demand, pricing power, and next-gen differentiation.
European obesity-drug sentiment pressured via Novo’s Copenhagen selloff; US obesity leadership sentiment supported via Lilly’s forecast beat.
Read-across risk for global obesity peers as investors benchmark oral pill uptake and pipeline efficacy against Lilly’s Zepbound.
Counterpoint
Novo’s management framed profitability improvement via higher-dose mix and manufacturing efficiency, which could offset near-term sales softness if execution holds.
Key entities
- companyNovo Nordisk
Wegovy sales underwhelmed; raised forecast; CagriSema trial comparison again lagged Zepbound.
- companyEli Lilly
Zepbound outperformed in CagriSema comparison; boosted forecast and reported better-than-expected earnings.
- productWegovy
Novo’s obesity weight-loss pill whose sales disappointed relative to hype.
- productCagriSema
Next-generation obesity shot that failed to match Zepbound in a study comparison.
- productZepbound
Lilly’s obesity drug that outperformed in the CagriSema comparison.
